Navigation Links
ISTO Technologies to Present at OneMedPlace Finance Forum
Date:12/20/2007

ST. LOUIS, Dec. 20 /PRNewswire/ -- ISTO Technologies, Inc., a privately held orthobiologic company, announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA from January 7-8, 2008. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Tuesday, January 8th at 11:00 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. Information about the OneMedPlace Finance Forum may be found at http://www.onemedplace.com.

ISTO's rich product pipeline includes DeNovo(R) ET, a tissue engineered cartilage implant in Phase I/II trials for resurfacing knee joints, NuQu(TM), a cartilage cell-based product in late-stage development for degenerated disc nucleus, and InQu(R), a biomaterial for bone regeneration that has received 510(k) clearance. ISTO's innovative products are designed to address very large markets with unmet clinical needs.

Cartilage regeneration is often called the "holy grail" of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a "shock absorber" protecting all joints, including spinal discs, from the wear and tear experienced during motion.

InQu represents a new class of biomaterial designed to offer a number of clinical advantages to surgeons and patients.

About ISTO

ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at http://www.istotech.com or contact the Company at 314-995-6049.


'/>"/>
SOURCE ISTO Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
(Date:7/1/2015)... July 1, 2015 InferMed ... will ... evidence-based clinical s olutions suite   ... medical information products and services, announced today the acquisition of  ... support (CDS) technology company. InferMed,s Arezzo technology supports ...
(Date:6/30/2015)... ... , ... Students and faculty from Beijing City University will ... Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. The ... both universities and is taught on both continents. , “Our alliance with Beijing ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... 2011 Cross reference:   Picture ... be downloaded free of charge at:   http://www.presseportal.de/pm/18701/eppendorf-ag?keygroup=bild ... Science from 2008, Dr. Andrew Holt and ... how chemicals used as manufacturing additives can substantially inhibit ...
... HANOVER, N.J., Dec. 2, 2011 Novartis Pharmaceuticals Corporation ... presentations on data from its robust oncology portfolio at ... for patients with cancers and hematological diseases. ... held from December 6-10, will feature data presentations from ...
... Ltd. - (OTCBB: HADSY), a publicly traded portfolio of ... owned by the Hadassah University Hospital, Israel,s foremost medical ... companies have received grant approvals from the Israeli Office ... Industry, Trade and Labor. These approvals ...
Cached Biology Technology:Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 3Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 4Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 5Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 6Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 7Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 8Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 9Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 10Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 11Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 12Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 13Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 14Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 15Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 16Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 17Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 18Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 19Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 20Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 21Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies 2
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... researchers and collaborators have found, in a previously identified ... five cases of isolated cleft lip. It is the ... cleft lip alone, rather than both cleft lip and ... unknown genetic mechanism and could eventually help with diagnosis, ...
... Journal of Cell Biology how the altered behavior ... On 2D surfaces, cells may migrate randomly, or be ... extracellular matrix, are known to influence the mode of ... has suggested that an integrin called a5b1 drives random ...
... New material could speed development of hydrogen powered vehicles ... design of a new material that almost meets the U.S. ... could help eliminate a key roadblock to practical hydrogen-powered vehicles. ... explosive gas, is scheduled for the Oct. 8 issue of ...
Cached Biology News:Study finds genetic variant plays role in cleft lip 2Study finds genetic variant plays role in cleft lip 3American Chemical Society's Weekly PressPac 2American Chemical Society's Weekly PressPac 3American Chemical Society's Weekly PressPac 4American Chemical Society's Weekly PressPac 5American Chemical Society's Weekly PressPac 6American Chemical Society's Weekly PressPac 7American Chemical Society's Weekly PressPac 8
... SYBR Green I nucleic acid gel stain ... that has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... acid stain has also found uses in capillary ...
Synonym: modified Grace's Insect medium...
... The active ingredient in Molecular ... which appears to act as a ... fluorescence emission. Our original SlowFade formulation ... fading rate of fluorescein to almost ...
... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
Biology Products: